(NASDAQ: PMVP) Pmv Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.7%.
Pmv Pharmaceuticals's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast PMVP's revenue for 2027 to be $1,712,830,003, with the lowest PMVP revenue forecast at $1,712,830,003, and the highest PMVP revenue forecast at $1,712,830,003. On average, 1 Wall Street analysts forecast PMVP's revenue for 2028 to be $3,663,696,804, with the lowest PMVP revenue forecast at $3,663,696,804, and the highest PMVP revenue forecast at $3,663,696,804.
In 2029, PMVP is forecast to generate $5,873,299,255 in revenue, with the lowest revenue forecast at $5,873,299,255 and the highest revenue forecast at $5,873,299,255.